RESCUE CHEMIOTERAPY WITH MI Mitomicina e Isofosfamide in pancreatic adenocarcinoma with metastasis a phase II study. - ND

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001163-29-IT

Enrollment

Registered

2006-03-14

Start date

2006-03-16

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with pancreatic adenocarcinoma in progression after previous chemioterapic therapy with Gemcitabina MedDRA version: 6.1 Level: PT Classification code 10052747

Interventions

Trade Name: HOLOXAN IV 1 FL 1000 MG Pharmaceutical Form: Solution for infusion INN or Proposed INN: Ifosfamide CAS Number: 3778-73-2 Concentration unit: g gram(s) Concentration type: equal Concentrati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: pancreatic carcinoma diagnosis with metastasis, previous chemioterpy, age 50 and 76 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: cerebral metastasis, pregnancy, previous chemiotherapy with ifosfamide or mytomicin

Design outcomes

Primary

Measure	Time frame
Main Objective: of patients free of progression after chemioterapy with Gemcitabina;Secondary Objective: objective respons, quality of life,survival rate;Primary end point(s): PF5-6	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026